/
/
Added Venetoclax Improves Myeloma Patient Outcomes
Added Venetoclax Improves Myeloma Patient Outcomes image
Added Venetoclax Improves Myeloma Patient Outcomes
Posted Jun 12, 2018

According to an ongoing study, the addition of venetoclax (Venclexta) to the combination therapy of carfilzomib (Kyprolis) and dexamethasone (Kd) resulted in very high responses to relapsed/refractory myeloma patients.

"Venetoclax plus Kd has shown promising preliminary efficacy," said lead investigator Luciano J. Costa, MD, PhD, associate professor of Medicine Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham. "Although responses are extremely high in the t(11;14), we also saw responses in patients at standard risk that were comparable to those with high-risk cytogenetic abnormalities."

With the noted results, Dr. Costa concluded that higher treatment dosage gives better outcomes.

Venetoclax is the only drug being used in clinical trials found to be specifically effective for patients with the 11;14 translocation (where parts of genes 11 and 14 have swapped places.)  For these patients, many myeloma specialists are using venetoclax in addition to other myeloma therapies whether the patient is newly diagnosed or relapsed. 

A phase III study is currently examining the addition of venetoclax to bortezomib and dexamethasone for patients with multiple myeloma, regardless of t(11;14) status. Expected completion is September 2019.

See this article to read more.

The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811